Cargando…

Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan

Background: Immune checkpoint inhibitors (ICIs) have significantly changed the current approach to cancer treatment. Although the use of ICIs has become the standard of care for advanced melanoma, reports of ICI use among Asian populations with melanoma are limited. Therefore, we conducted this retr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Chiao-En, Yang, Chan-Keng, Peng, Meng-Ting, Huang, Pei-Wei, Lin, Yu-Fen, Cheng, Chi-Yuan, Chang, Yao-Yu, Chen, Huan-Wu, Hsieh, Jia-Juan, Chang, John Wen-Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287159/ https://www.ncbi.nlm.nih.gov/pubmed/32582554 http://dx.doi.org/10.3389/fonc.2020.00905

Ejemplares similares

A Cohort Study: Comorbidity and Stage Affected the Prognosis of Melanoma Patients in Taiwan
por: Chang, Chin-Kuo, et al.
Publicado: (2022)

Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma
por: Chang, John Wen‐Cheng, et al.
Publicado: (2023)

The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study
por: Hsu, Jason C., et al.
Publicado: (2021)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma
por: Pan, Chaohu, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review
por: Zheng, Qingyue, et al.
Publicado: (2020)

Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis
por: Sun, You-Meng, et al.
Publicado: (2021)

Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
por: Jessurun, Charissa A. C., et al.
Publicado: (2017)

De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma
por: Ma, Si-Cong, et al.
Publicado: (2021)

The association between tyrosine kinase inhibitors and fatal arrhythmia in patients with non-small cell lung cancer in Taiwan
por: Chang, Wei-Ting, et al.
Publicado: (2023)

Risk factors for venous port migration in a single institute in Taiwan
por: Fan, Wen-Chieh, et al.
Publicado: (2014)

Merkel cell carcinoma in Taiwan: A series of 24 cases and literature review
por: Chang, John Wen-Cheng, et al.
Publicado: (2019)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer
por: Han, Xiling, et al.
Publicado: (2022)

Case Report: Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant Melanoma
por: Schmidt, Teresa, et al.
Publicado: (2021)

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
por: Wu, Chiao-En, et al.
Publicado: (2020)

Multidisciplinary Taiwan consensus for the use of conventional TACE in hepatocellular carcinoma treatment
por: Chang, Pi-Yi, et al.
Publicado: (2023)

Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients
por: Jiang, Shuai, et al.
Publicado: (2022)

Response of Metastatic Chordoma to the Immune Checkpoint Inhibitor Pembrolizumab: A Case Report
por: Wu, Xiaoli, et al.
Publicado: (2020)

Factors Predicting Oncological Outcomes of Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma in Taiwan
por: Chen, I-Hsuan Alan, et al.
Publicado: (2022)

Hepatic arterial infusion chemotherapy and immune checkpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: a single-centre experience in Taiwan
por: Wu, Juei-Seng, et al.
Publicado: (2023)

Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice
por: Kuo, Ming-Chun, et al.
Publicado: (2020)

IDO Inhibitor and Gallic Acid Cross-Linked Small Molecule Drug Synergistic Treatment of Melanoma
por: Liu, Hongmei, et al.
Publicado: (2022)

Toxicities of Immune Checkpoint Inhibitors: Itis-Ending Adverse Reactions and More
por: Ellithi, Moataz, et al.
Publicado: (2020)

Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan
por: Hsu, Jason C., et al.
Publicado: (2018)

Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
por: Liang, Sheng-Kai, et al.
Publicado: (2021)

Sentinel Lymph Node Biopsy Was Associated With Favorable Survival Outcomes For Patients With Clinically Node-Negative Asian Melanoma
por: Chang, John Wen-Cheng, et al.
Publicado: (2019)

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
por: Wu, Y. Linda, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators
por: Byun, Hwa Kyung, et al.
Publicado: (2021)

Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers
por: Chai, Annie Wai Yeeng, et al.
Publicado: (2022)

Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data
por: Rao, Hui, et al.
Publicado: (2023)

Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma
por: Mehdi, Ali, et al.
Publicado: (2020)

Idiopathic Mesenteric Phlebosclerosis: A Single-Institute Experience in Taiwan
por: Chou, Jen-Wei, et al.
Publicado: (2023)

Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma
por: Hung, Hao-Chien, et al.
Publicado: (2021)

Chromosomal Instability May Not Be a Predictor for Immune Checkpoint Inhibitors from a Comprehensive Bioinformatics Analysis
por: Wu, Chiao-En, et al.
Publicado: (2020)

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors
por: Wu, Leilei, et al.
Publicado: (2020)

Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis
por: Sun, Qian, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-induced Fanconi Syndrome
por: Farid, Saira, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uobm2ut6e89c2rofncpog7l0kr